期刊
RADIOTHERAPY AND ONCOLOGY
卷 127, 期 3, 页码 423-430出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2018.05.002
关键词
Locally advanced cervical cancer; MRI-guided adaptive brachytherapy; Bladder morbidity
资金
- Nucletron
- Elekta company
- Varian Medical System
- Vienna Medical University
- Danish Cancer Society [R125-A7753-15-S37]
Background and purpose: The EMBRACE study is a prospective multi-institutional study on MRI guided adaptive brachytherapy (IGABT) in locally advanced cervix cancer (LACC). This analysis describes early to late urinary morbidity assessed by physicians and patients (PRO). Material and methods: A total of 1176 patients were analysed. Median follow up (FU) was 27 (1-83) months. Morbidity (CTCAE v.3) and PRO (EORTC QLQ-C30& CX24) was prospectively assessed at baseline (BL), and during FU. Results: The most frequent symptoms were frequency/urgency, incontinence, and cystitis with grade 2-4 prevalence rates of 4.3%, 5.0% and 1.7% and grade 1-4 prevalence rates of 24.5%, 16.1% and 5.8% at 3-years. The most frequent PRO endpoints were urinary frequency and leaking of urine. Prevalence of Quite a bit or very much bother fluctuated from 14.0% to 21.5% for frequency, while leaking of urine increased from 4.6% at BL to 9.3% at 3-years. Actuarial 3-year incidence of grade 3-4 urinary morbidity was 5.3% with most events being urinary frequency, incontinence and ureteral strictures. Grade 3-4 fistula, bleeding, spasm and cystitis were all <1.0% at 3/5-years. No grade 5 toxicity occurred. Conclusion: Urinary grade 3-4 morbidity with IGABT was limited. Urinary morbidity grade 2-4 comprises mainly frequency/urgency, incontinence and cystitis and has considerable prevalence in PRO. Various urinary morbidity endpoints have different patterns of manifestation and time course. (C) 2018 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据